Return to content in this issue

 

Early effectivity of dupilumab in patients with t2 severe asthma: a prospective real-life study

Castilla-Martínez M1, Andújar-Espinosa R2,3, Flores-Martín I4, Reyes Cotes MH5, Cabrejos-Perotti S6, Miralles-López JC7, Carbonell-Martínez A8, Bravo-Gutiérrez FJ9, Valverde-Molina J10, Pérez-Fernández V11, RE-ASGRAMUR GROUP*

1 Pulmonology Department. University General Hospital Los Arcos. San Javier, Murcia, Spain
2 Pulmonology Department. University Clinic Hospital Virgen de la Arrixaca. Murcia, Spain
3 Medicine Department. University of Murcia. Murcia, Spain
4 Allergy Department. University General Hospital Santa Lucia. Cartagena, Murcia, Spain
5 Pulmonology Department. Northwest County Hospital, Caravaca, Murcia, Spain
6 Allergy Department. General Hospital Rafael Méndez. Lorca, Murcia, Spain
7 Allergy Department. University General Hospital Reina Sofía. Murcia, Spain
8 Allergy Department. La Fama Medical Center. Murcia, Spain
9 Pulmonology Department. University General Hospital Santa Lucia. Cartagena, Murcia, Spain
10 Pediatrics Department. University General Hospital Santa Lucia. Cartagena, Murcia, Spain
11 Department of Public Health Sciences. University of Murcia School of Medicine. Murcia, Spain
* Members of the RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) Group are listed in Supplementary Appendix 1

J Investig Allergol Clin Immunol 2023; Vol. 33(4)
doi: 10.18176/jiaci.0872

Key words: Severe asthma, Dupilumab, Real-life, T2 inflammation